Effect of low molecular weight heparins and fondaparinux upon thrombin generation triggered by human pancreatic cancer cells BXPC3

Current Vascular Pharmacology

Volumn 12, Issue 6, 2014, Pages 893-902

  Gerotziafas, Grigoris T ^a,b   Galea, Vassiliki ^a,b   Mbemba, Elisabeth ^a   Sassi, Mouna ^a,b   Roman, Marie Paule ^a,b   Khaterchi, Amir ^a,b   van Dreden, Patrick ^c   Japcowitz, Max ^d   Lotz, Jean Pierre ^d   Bernaudin, Jean François ^a,e   Fareed, Jawed ^f   Hatmi, Mohamed ^b,g   Elalamy, Ismail ^a,b  

^a SORBONNE UNIVERSITÉ   (France)

^b ARMAND TROUSSEAU HOSPITAL   (France)

^c Diagnositca Stago ^*  (France)

^d HÔPITAL TENON   (France)

^e ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^f LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^g INSTITUT PASTEUR   (France)

Author keywords

Anti Xa activity; BXPC3; Fondaparinux; LMWH; Pancreatic cancer; Thrombin generation; Tissue factor

Indexed keywords

BLOOD CLOTTING FACTOR 10A; DALTEPARIN; ENOXAPARIN; FONDAPARINUX; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PROTHROMBIN A; THROMBIN; TINZAPARIN; ANTICOAGULANT AGENT; POLYSACCHARIDE;

ANTITHROMBOTIC ACTIVITY; ARTICLE; DRUG ACTIVITY; DRUG MECHANISM; ENDOGENOUS THROMBIN POTENTIAL; HEMATOLOGICAL PARAMETERS; HUMAN; HUMAN CELL; IC50; MEAN RATE INDEX; PLASMA; THROMBIN TIME; THROMBOCYTE POOR PLASMA; THROMBOCYTE RICH PLASMA; ANTAGONISTS AND INHIBITORS; METABOLISM; PANCREATIC NEOPLASMS; TREATMENT OUTCOME;

ANTICOAGULANTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; PANCREATIC NEOPLASMS; POLYSACCHARIDES; THROMBIN; TREATMENT OUTCOME;

EID: 84926378133     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/157016111206141210121441     Document Type: Article

References (35)

1. Trousseau A. Phlegmasia alba dolens. In: Trousseau A, Ed. Clinique medicale de l’Hotel Dieu de Paris. Paris: Balllier 1865; pp. 654-12.
2. Heit JA, Mohr DN, Silverstein MD, Petterson TM, O'Fallon WM, Melton LJ 3rd. Predictors of recurrence after deep vein thrombosis and pulmonary embolism. Arch Intern Med 2000; 160: 761-8.
3. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005; 293: 715-22.
4. Connolly GC, Khorana AA. Risk stratification for cancerassociated venous thromboembolism. Best Pract Res Clin Haematol 2009; 22: 35-47.
5. Wun T, White RH. Venous thromboembolism (VTE) in patients with cancer: epidemiology and risk factors. Cancer Invest 2009; 27: 63-74.
6. Khorana AA, Fine RL. Pancreatic cancer and thromboembolic disease. Lancet Oncol 2004; 5: 655-63.
7. Menapace LA, Peterson DR, Berry A, Sousou T, Khorana AA. Symptomatic and incidental thromboembolism are both associated with mortality in pancreatic cancer. Thromb Haemost 2011; 106: 371-8.
8. Lyman GH. Venous thromboembolism in the patient with cancer: focus on burden of disease and benefits of thromboprophylaxis. Cancer 2011; 117: 1334-49.
9. Tufano A, Coppola A, Cerbone AM, Ruosi C, Franchini M. Preventing postsurgical venous thromboembolism: pharmacological approaches. Semin Thromb Hemost 2011; 37: 252-66.
10. Akl EA, Vasireddi SR, Gunukula S, et al. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev 2011; 6: CD006649.
11. Agnelli G, Gussoni G, Bianchini C, et al. PROTECHT Investigators. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol 2009; 10: 943-9.
12. Shah MM, Saif MW. Pancreatic cancer and thrombosis. Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010. JOP 2010; 11: 331-3.
13. Gerotziafas GT, Petropoulou AD, Verdy E, Samama MM, Elalamy I. Effect of the anti-factor Xa and anti-factor IIa activities of lowmolecular-weight heparins upon the phases of thrombin generation. J Thromb Haemost 2007; 5: 955-62.
14. Orfeo T, Gissel M, Butenas S, Undas A, Brummel-Ziedins KE, Mann KG. Anticoagulants and the propagation phase of thrombin generation. PLoS One 2011; 6: e27852.
15. Gerotziafas GT, Galea V, Mbemba E, et al. Tissue factor overexpression by human pancreatic cancer cells BXPC3 is related to higher prothrombotic potential as compared to breast cancer cells MCF7. Thromb Res 2012; 129: 779-86.
16. Depasse F, Gerotziafas GT, Busson J, Van Dreden P, Samama MM. Assessment of three chromogenic and one clotting assays for the measurement of synthetic pentasaccharide fondaparinux (Arixtra) anti-Xa activity. J Thromb Haemost 2004; 2: 346-8.
17. Gerotziafas GT, Chakroun T, Depasse F, Arzoglou P, Samama MM, Elalamy I. The role of platelets and recombinant factor VIIa on thrombin generation, platelet activation and clot formation. Thromb Haemost 2004; 91: 977-85.
18. Gerotziafas GT, Depasse F, Busson J, Leflem L, Elalamy I, Samama MM. Towards a standardization of thrombin generation assessment: the influence of tissue factor, platelets and phospholipids concentration on the normal values of Thrombogram-Thrombinoscope assay. Thromb J 2005; 3: 16.
19. Spronk HM, Dielis AW, De Smedt E, et al. Assessment of thrombin generation II: Validation of the Calibrated Automated Thrombogram in platelet-poor plasma in a clinical laboratory. Thromb Haemost 2008; 100: 362-4.
20. Dargaud Y, Luddington R, Gray E, et al. Standardisation of thrombin generation test--which reference plasma for TGT? An international multicentre study. Thromb Res 2010; 125: 353-6.
21. Mikhailidis DP, Kakafika A, Papadopoulos V, Mimidis K. Coagulation, platelets and acute pancreatitis. Pancreas 2007; 34: 1-6.
22. Hacquard M, Perrin J, Lelievre N, Vigneron C, Lecompte T. Interindividual variability of effect of 7 low molecular weight antithrombin-dependent anticoagulants studied in vitro with calibrated automated thrombography. Thromb Res 2011; 127: 29-34.
23. Ben-Hadj-Khalifa S, Hézard N, Almawi WY, et al. Differential coagulation inhibitory effect of fondaparinux, enoxaparin and unfractionated heparin in cell models of thrombin generation. Blood Coagul Fibrinolys 2011; 22: 369-73.
24. Barrowcliffe TW, Havercroft SJ, Kemball-Cook G, Lindhal U. The effect of Ca2+, phospholipids and factor V on the anti-factor Xa activity of heparin and its oligosaccharides. Biochem J 1987; 243: 31-7.
25. Pieters J, Willemsg G, Hernker HC, Lindhout T. Inhibition of factor IXa and factor X, by Antithrombin III/Heparin during factor X activation. J Biol Chem 1988; 263: 15313-8.
26. Hemker HC, Choay J, Beguin S. Free factor Xa is on the main pathway of thrombin generation in clotting plasma. Biochim Biophys Acta 1989; 992: 409-11.
27. Herault JP, Bernat A, Pflieger AM, Lormeau JC, Herbert JM. Comparative effects of two direct and indirect factor Xa inhibitors on free and clot-bound prothrombinase. J Pharmacol Exp Ther 1997; 283: 16-22.
28. Rezaie AR. Prothrombin protects factor Xa in the prothrombinase complex from inhibition by the heparin-antithrombin complex. Blood 2001; 97: 2308-13.
29. ten Cate H, Falanga A. Overview of the postulated mechanisms linking cancer and thrombosis. Pathophysiol Haemost Thromb 2008; 36: 122-30.
30. Theocharis AD, Skandalis SS, Tzanakakis GN, Karamanos NK. Proteoglycans in health and disease: novel roles for proteoglycans in malignancy and their pharmacological targeting. FEBS J 2010; 277: 3904-23.
31. Barash U, Cohen-Kaplan V, Dowek I, Sanderson RD, Ilan N, Vlodavsky I. Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis. FEBS J 2010; 277: 3890-903.
32. Zuckerman L, Ramstack JM, Vagher JP, Caprini JA, Mockros LF. Neutralization of heparin by cellular blood elements. Thromb Res 1975; 7: 149-59.
33. Fareed J, Walenga JM, Hoppensteadt D, Huan X, Racanelli A. Comparative study on the in vitro and in vivo activities of seven low-molecular-weight heparins. Haemostasis 1988; 18(Suppl 3): 3-15.
34. Hemker HC, Béguin S. Mode of action of unfractionated and low molecular weight heparins on the generation of thrombin in plasma. Haemostasis 1990; 20(Suppl 1): 81-92.
35. Jagroop IA, Barradas MA, Mikhailidis DP. A low molecular weight heparin, nadroparin (Fraxiparine), inhibits thrombininduced platelet shape change and does not enhance spontaneous platelet aggregation. Br J Clin Pharmacol 1996; 41: 163-5.